156 related articles for article (PubMed ID: 35776862)
1. Omadacycline in Skin Infections and Pneumonia: A Review of the Evidence.
Vacalis S; Brunton S; Gindi J
J Fam Pract; 2022 Jun; 71(5 Suppl):S10-S21. PubMed ID: 35776862
[TBL] [Abstract][Full Text] [Related]
2. Safety and efficacy of omadacycline for treatment of community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections in patients with mild-to-moderate renal impairment.
Cornely OA; File TM; Garrity-Ryan L; Chitra S; Noble R; McGovern PC
Int J Antimicrob Agents; 2021 Feb; 57(2):106263. PubMed ID: 33326848
[TBL] [Abstract][Full Text] [Related]
3. Omadacycline: A Novel Oral and Intravenous Aminomethylcycline Antibiotic Agent.
Zhanel GG; Esquivel J; Zelenitsky S; Lawrence CK; Adam HJ; Golden A; Hink R; Berry L; Schweizer F; Zhanel MA; Bay D; Lagacé-Wiens PRS; Walkty AJ; Lynch JP; Karlowsky JA
Drugs; 2020 Feb; 80(3):285-313. PubMed ID: 31970713
[TBL] [Abstract][Full Text] [Related]
4. Once-daily oral omadacycline versus twice-daily oral linezolid for acute bacterial skin and skin structure infections (OASIS-2): a phase 3, double-blind, multicentre, randomised, controlled, non-inferiority trial.
O'Riordan W; Cardenas C; Shin E; Sirbu A; Garrity-Ryan L; Das AF; Eckburg PB; Manley A; Steenbergen JN; Tzanis E; McGovern PC; Loh E;
Lancet Infect Dis; 2019 Oct; 19(10):1080-1090. PubMed ID: 31474458
[TBL] [Abstract][Full Text] [Related]
5. Omadacycline for Acute Bacterial Skin and Skin Structure Infections.
Abrahamian FM; Sakoulas G; Tzanis E; Manley A; Steenbergen J; Das AF; Eckburg PB; McGovern PC
Clin Infect Dis; 2019 Aug; 69(Suppl 1):S23-S32. PubMed ID: 31367742
[TBL] [Abstract][Full Text] [Related]
6. Omadacycline for Acute Bacterial Skin and Skin-Structure Infections.
O'Riordan W; Green S; Overcash JS; Puljiz I; Metallidis S; Gardovskis J; Garrity-Ryan L; Das AF; Tzanis E; Eckburg PB; Manley A; Villano SA; Steenbergen JN; Loh E
N Engl J Med; 2019 Feb; 380(6):528-538. PubMed ID: 30726689
[TBL] [Abstract][Full Text] [Related]
7. Omadacycline: A New Tetracycline Antibiotic.
Dougherty JA; Sucher AJ; Chahine EB; Shihadeh KC
Ann Pharmacother; 2019 May; 53(5):486-500. PubMed ID: 30917674
[TBL] [Abstract][Full Text] [Related]
8. Omadacycline Oral Dosing and Pharmacokinetics in Community-Acquired Bacterial Pneumonia and Acute Bacterial Skin and Skin Structure Infection.
Leviton IM; Amodio-Groton M
Clin Drug Investig; 2022 Mar; 42(3):193-197. PubMed ID: 35192150
[TBL] [Abstract][Full Text] [Related]
9. An Integrated Safety Summary of Omadacycline, a Novel Aminomethylcycline Antibiotic.
Opal S; File TM; van der Poll T; Tzanis E; Chitra S; McGovern PC
Clin Infect Dis; 2019 Aug; 69(Suppl 1):S40-S47. PubMed ID: 31367740
[TBL] [Abstract][Full Text] [Related]
10. Omadacycline for Community-Acquired Bacterial Pneumonia.
Stets R; Popescu M; Gonong JR; Mitha I; Nseir W; Madej A; Kirsch C; Das AF; Garrity-Ryan L; Steenbergen JN; Manley A; Eckburg PB; Tzanis E; McGovern PC; Loh E
N Engl J Med; 2019 Feb; 380(6):517-527. PubMed ID: 30726692
[TBL] [Abstract][Full Text] [Related]
11. Omadacycline: a therapeutic review of use in community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections.
Chopra T; Sandhu A; Theriault N; Meehan J; Tillotson G
Future Microbiol; 2020 Sep; 15():1319-1333. PubMed ID: 32959689
[TBL] [Abstract][Full Text] [Related]
12. Omadacycline: A Modernized Tetracycline.
Gallagher JC
Clin Infect Dis; 2019 Aug; 69(Suppl 1):S1-S5. PubMed ID: 31367739
[TBL] [Abstract][Full Text] [Related]
13. Safety and efficacy of omadacycline by BMI categories and diabetes history in two Phase III randomized studies of patients with acute bacterial skin and skin structure infections.
Pai MP; Wilcox MH; Chitra S; McGovern PC
J Antimicrob Chemother; 2021 Apr; 76(5):1315-1322. PubMed ID: 33458763
[TBL] [Abstract][Full Text] [Related]
14. Omadacycline vs moxifloxacin in adults with community-acquired bacterial pneumonia.
Torres A; Garrity-Ryan L; Kirsch C; Steenbergen JN; Eckburg PB; Das AF; Curran M; Manley A; Tzanis E; McGovern PC
Int J Infect Dis; 2021 Mar; 104():501-509. PubMed ID: 33484864
[TBL] [Abstract][Full Text] [Related]
15. Omadacycline in the treatment of community-acquired bacterial pneumonia in patients with comorbidities: a
Rodriguez GD; Warren N; Yashayev R; Chitra S; Amodio-Groton M; Wright K
Front Med (Lausanne); 2023; 10():1225710. PubMed ID: 37575994
[TBL] [Abstract][Full Text] [Related]
16. Omadacycline in treating community-based infections: a review and expert perspective.
Sakoulas G; Nowak M; Geriak M
Expert Rev Anti Infect Ther; 2023 Mar; 21(3):255-265. PubMed ID: 36718489
[TBL] [Abstract][Full Text] [Related]
17. A Review of Omadacycline for Potential Utility in the Military Health System for the Treatment of Wound Infections.
Zurawski DV; Serio AW; Black C; Pybus B; Akers KS; Deck DH; Johnson S; Chattagul S; Noble SM; Raynor M; Lanteri CA
Mil Med; 2024 May; 189(5-6):e1353-e1361. PubMed ID: 37963013
[TBL] [Abstract][Full Text] [Related]
18. Omadacycline: development of a novel aminomethylcycline antibiotic for treating drug-resistant bacterial infections.
Villano S; Steenbergen J; Loh E
Future Microbiol; 2016 Oct; 11():1421-1434. PubMed ID: 27539442
[TBL] [Abstract][Full Text] [Related]
19. Omadacycline: First Global Approval.
Markham A; Keam SJ
Drugs; 2018 Dec; 78(18):1931-1937. PubMed ID: 30471003
[TBL] [Abstract][Full Text] [Related]
20. Decision Analysis: Omadacycline Relative to Moxifloxacin Among Hospitalized Community-Acquired Bacterial Pneumonia Patients at Risk of Clostridioides difficile Infection.
Lodise TP; Mistry R; Young K; LaPensee K
Clin Drug Investig; 2021 Mar; 41(3):269-275. PubMed ID: 33604769
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
